Diethylcarbamazine citrate

Synonyms: 枸橼酸乙胺嗪
Diethylcarbamazine citrate 是一种具有口服活性的杀微丝蚴剂,最初用于治疗盘尾丝虫病和淋巴丝虫病,可减少嗜酸性粒细胞向肺组织的迁移并发挥抗过敏作用,还可降低血清瘦素、TNF-α、IL-6、MCP-1、葡萄糖、胰岛素和甘油三酯水平、改善胰岛素抵抗且不改变体重、肝脏或脂肪组织重量,同时能增强多形核中性粒细胞的活性氧中间体表达、促进淋巴细胞增殖并抑制放线菌肿病灶的发展,因此可用于支气管哮喘、胰岛素抵抗及感染相关研究。
产品编号: MS-H11045 纯度: 98.01% CAS No.: 1642-54-2 分子式: C16H29N3O8 分子量: 391.42
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

Diethylcarbamazine citrate 是一种具有口服活性的杀微丝蚴剂,最初用于治疗盘尾丝虫病和淋巴丝虫病,可减少嗜酸性粒细胞向肺组织的迁移并发挥抗过敏作用,还可降低血清瘦素、TNF-α、IL-6、MCP-1、葡萄糖、胰岛素和甘油三酯水平、改善胰岛素抵抗且不改变体重、肝脏或脂肪组织重量,同时能增强多形核中性粒细胞的活性氧中间体表达、促进淋巴细胞增殖并抑制放线菌肿病灶的发展,因此可用于支气管哮喘、胰岛素抵抗及感染相关研究。

生物实验数据

生物活性 Diethylcarbamazine citrate is an orally active microfilaricide originally used for the treatment of onchocerciasis and lymphatic filariasis that reduces eosinophil migration to lung tissue and exerts anti-allergic effects, lowers serum leptin, TNF-α, IL-6, MCP-1, glucose, insulin, and triglyceride levels and improves insulin resistance without altering body weight, liver weight, or adipose tissue weight, and enhances reactive oxygen intermediate expression in polymorphonuclear neutrophils, promotes lymphocyte proliferation, and inhibits the development of actinomycetoma lesions, making it useful for research on bronchial asthma, insulin resistance, and infection-related conditions.
IC50 & Target

IL-6

 

体外研究
(In Vitro)

Diethylcarbamazine (0-40 mM; 60 min) citrate cross-reacts with rabbit anti-MPCA-BSA polyclonal IgG antibodies in an inhibition ELISA.

体内研究
(In Vivo)

Diethylcarbamazine (12 mg/kg;口服) citrate 可在 Ovalbumin (MS-Q48215) 诱导的哮喘小鼠中发挥抗过敏作用;预先给予 40 mg/kg 的 Quercetin (MS-Q75882) 可显著增强该作用,表现为血清 Th2 细胞因子、支气管肺泡灌洗液 (BALF) IgE、肺嗜酸性粒细胞标志物水平降低,且肺部组织病理学损伤完全消退。
Diethylcarbamazine (12-200 mg/kg;口服;每周 2 次;12 周) citrate 可通过抑制脂肪组织炎症,显著改善雄性瑞士小鼠中高脂饮食诱导的胰岛素抵抗,其最优剂量为 50 mg/kg,且不影响小鼠的体重或组织重量;该剂量可显著降低血清葡萄糖、胰岛素、甘油三酯、促炎介质水平,以及肝脏环氧合酶活性与 NF-κBp65 核转位。
Diethylcarbamazine (6 mg/kg;口服;每日;1 周) citrate 可抑制 BALB/c 小鼠放线菌足肿病的发展,使病灶大小出现具有统计学意义的降低,并增强细胞免疫应答,包括中性粒细胞活性氧中间体的产生和淋巴细胞增殖。

Animal Model: white albino mice (6 to 8-week-old female, 18-20 g, intradermal sensitization + aerosol exposure Ovalbumin-induced asthma)
Dosage: 12 mg/kg
Administration: p.o.;
Result: Reduced serum IL-4 and IL-5, total BALF IgE and specific anti-ovalbumin IgE, lung tissue EPO and eotaxin2, and reduced inflammatory cell infiltration and thickened alveolar walls compared to untreated asthmatic mice.
Showed no significant changes in serum IL-4, IL-5, BALF IgE, lung EPO, or eotaxin2, and similar histopathological improvement compared to DEC alone when preceded by anti-DEC antibody.
Showed no significant changes in serum IL-4, IL-5, lung EPO, or eotaxin2, and partial reduction in inflammatory cell infiltration and alveolar wall thickening compared to DEC alone when preceded by 10 mg/kg Quercetin.
Significantly reduced serum IL-4 and IL-5, increased IFN-γ/IL-4 ratio to near control levels, decreased total BALF IgE, and reduced inflammatory cell infiltration compared to DEC alone when preceded by 20 mg/kg and 40 mg/kg Quercetin.
Animal Model: Swiss mice (male, 5 weeks old, initial 10 g body weight, high-fat diet-induced insulin resistance)
Dosage: 12 mg/kg; 50 mg/kg; 200 mg/kg
Administration: p.o.; twice weekly; 12 weeks (from 6 to 18 week)
Result: Reduced serum glucose levels at all oral glucose tolerance test time points (0, 30, 60, 120 min) with a statistically significant reduction in area under the curve at 50 mg/kg.
Reduced serum triglyceride levels at 50 mg/kg.
Reduced serum insulin levels and HOMA-IR score at 50 mg/kg.
Reduced serum leptin levels at 50 mg/kg.
Reduced serum levels of TNF-α, IL-6, and MCP-1 at 50 mg/kg.
Significantly reduced liver cyclooxygenase activity at 50 mg/kg.
Significantly inhibited nuclear localization of NF-κBp65 with increased cytoplasmic retention at 50 mg/kg.
Showed no statistically significant reductions in serum glucose, triglycerides, insulin, HOMA-IR, leptin, TNF-α, IL-6, MCP-1, or liver cyclooxygenase activity relative to untreated high-fat diet-fed mice at 12 mg/kg and 200 mg/kg.
Exhibited less potent effects on NF-κBp65 nuclear localization at 12 mg/kg and 200 mg/kg compared to 50 mg/kg.
Caused no significant changes to body, adipose tissue, or liver weights at 50 mg/kg.
Animal Model: BALB/c (male, 10-12 weeks old, 37-45 g, actinomycetoma model via footpad inoculation with Nocardia brasiliensis)
Dosage: 6 mg/kg
Administration: p.o.; daily; 1 week
Result: Reduced actinomycetoma lesion size with statistical significance compared to untreated infected controls.
Resolved fistulae, granule discharge, hyperemia, and erythema by day 20 post-infection, and prevented mycetoma establishment through day 90.
Reduced cellular infiltrate, eliminated granuloma layer formation, restored epidermal integrity, and reorganized damaged striated muscle fibers by day 28 post-infection.
Enhanced polymorphonuclear neutrophil reactive oxygen intermediate production with statistical significance at day 3 post-infection.
Increased lymphocyte proliferation in response to N.
brasiliensis cellular crude extract with statistical significance at day 21 post-infection.
Increased lymphocyte proliferation in response to concanavalin A with statistical significance at day 28 post-infection.
Caused no significant changes in IgG or IgM antibody production against N.
brasiliensis P24 antigen.
性状 固体
颜色 White to off-white

化学信息

分子量 391.42
分子式 C16H29N3O8
CAS No. 1642-54-2
别名 枸橼酸乙胺嗪

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.11 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 100 mg/mL (255.48 mM; 超声助溶)

DMSO 中的溶解度 : ≥ 39 mg/mL (99.64 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM2.5548 mL12.7740 mL25.5480 mL63.8700 mL
5 mM0.5110 mL2.5548 mL5.1096 mL12.7740 mL
10 mM0.2555 mL1.2774 mL2.5548 mL6.3870 mL
15 mM0.1703 mL0.8516 mL1.7032 mL4.2580 mL
20 mM0.1277 mL0.6387 mL1.2774 mL3.1935 mL
25 mM0.1022 mL0.5110 mL1.0219 mL2.5548 mL
30 mM0.0852 mL0.4258 mL0.8516 mL2.1290 mL
40 mM0.0639 mL0.3194 mL0.6387 mL1.5968 mL
50 mM0.0511 mL0.2555 mL0.5110 mL1.2774 mL
60 mM0.0426 mL0.2129 mL0.4258 mL1.0645 mL
80 mM0.0319 mL0.1597 mL0.3194 mL0.7984 mL
H2O100 mM0.0255 mL0.1277 mL0.2555 mL0.6387 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础